CN111683928A - 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 - Google Patents

作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 Download PDF

Info

Publication number
CN111683928A
CN111683928A CN201980012023.5A CN201980012023A CN111683928A CN 111683928 A CN111683928 A CN 111683928A CN 201980012023 A CN201980012023 A CN 201980012023A CN 111683928 A CN111683928 A CN 111683928A
Authority
CN
China
Prior art keywords
compound
group
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012023.5A
Other languages
English (en)
Other versions
CN111683928B (zh
Inventor
张杨
付志飞
罗妙荣
任在方
胡东杰
李婕
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Medshine Discovery Inc
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN111683928A publication Critical patent/CN111683928A/zh
Application granted granted Critical
Publication of CN111683928B publication Critical patent/CN111683928B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

本发明公开了式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐，并涉及其在制备治疗与FGFR相关疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201980012023.5A 2018-02-08 2019-02-02 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 Active CN111683928B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101306313 2018-02-08
CN201810130631 2018-02-08
PCT/CN2019/074576 WO2019154364A1 (zh) 2018-02-08 2019-02-02 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物

Publications (2)

Publication Number Publication Date
CN111683928A true CN111683928A (zh) 2020-09-18
CN111683928B CN111683928B (zh) 2021-12-10

Family

ID=67548769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012023.5A Active CN111683928B (zh) 2018-02-08 2019-02-02 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物

Country Status (6)

Country Link
US (1) US11286248B2 (zh)
EP (1) EP3750880B1 (zh)
JP (1) JP7168149B2 (zh)
CN (1) CN111683928B (zh)
ES (1) ES2936627T3 (zh)
WO (1) WO2019154364A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7198387B2 (ja) * 2019-08-08 2022-12-28 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 ピラジン－２（１ｈ）－オン系化合物のｃ結晶形とｅ結晶形及びその製造方法
WO2021023192A1 (zh) * 2019-08-08 2021-02-11 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
CN114174272B (zh) * 2019-08-08 2023-05-12 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的制备方法
US11597722B2 (en) 2019-08-08 2023-03-07 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101468965A (zh) * 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2820009B1 (en) * 2012-03-01 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101468965A (zh) * 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环

Also Published As

Publication number Publication date
CN111683928B (zh) 2021-12-10
JP7168149B2 (ja) 2022-11-09
ES2936627T3 (es) 2023-03-21
EP3750880A4 (en) 2021-10-27
EP3750880B1 (en) 2022-12-21
US11286248B2 (en) 2022-03-29
US20210040070A1 (en) 2021-02-11
JP2021523875A (ja) 2021-09-09
WO2019154364A1 (zh) 2019-08-15
EP3750880A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
TWI690531B (zh) Ｊａｋ抑制劑
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
CN111372925B (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
BR112020001124A2 (pt) composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto ou do sal farmaceuticamente aceitável do mesmo e método para tratamento de câncer
EP3333157B1 (en) Vinyl compounds as fgfr and vegfr inhibitors
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
TWI749126B (zh) Cdk4/6抑制劑
CN111712499A (zh) 一种atr抑制剂及其应用
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
JP2020500908A (ja) Ｃｃｒ２／ｃｃｒ５受容体拮抗剤としてのビフェニル化合物
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
CN109661391A (zh) S1p1激动剂及其应用
CN109071469B (zh) 三环类化合物及其应用
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
WO2023081637A1 (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
WO2023077259A1 (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
EP3766883B1 (en) Imidaxopyrolone compound and application thereof
JP2019518052A (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 363000 No. 1, Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province

Applicant after: Zhangzhou Pianzihuang Pharmaceutical Co., Ltd

Address before: 363000, Fujian, Zhangzhou streets

Applicant before: Zhangzhou Pianzihuang Pharmaceutical Co., Ltd

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant